


Company

Dallah Healthcare

3Q25 Result Review

Rating**Hold****Bloomberg Ticker****DALLAH AB****Date**

5 November 2025

Results**Target Price SAR** 142.0**Upside/ Downside** -5.3%**Revenue posts strong growth in 3Q25, in line with our estimate**

Dallah Healthcare's revenue jumped 25% YoY in 3Q25 on the back of increased operational capacity and strategic inorganic expansions, meeting our expectations. About 87% of the total revenue growth in 3Q25 came from Al-Khobar hospital and Al-Ahsa hospital, which were acquired in March 2025.

Net profit rises at a relatively slower pace than revenue in 3Q25

Net profit grew 12% YoY in 3Q25, primarily driven by strong revenue growth. The company booked a SAR 29.5mn remeasurement profit in 3Q25, as it successfully negotiated a reduction in the Murabaha rate, which also contributed to the result. However, net loss at Dallah Al-Khobar Hospital likely constrained the overall net profit growth during the quarter, although the loss reduced by 95% YoY.

U Capital View

Following the 3Q25 outturn, we await the release of detailed financials and maintain our SAR 142.0/share target price on Dallah as of now. The BoD has proposed a dividend of SAR 0.5/share for 3Q25, maintaining its quarterly trend, indicating a payout ratio of 36%.

Financial Summary

SAR mn	3Q24	4Q24	1Q25	2Q25	3Q25	3Q25e	YoY	QoQ	Var.	9M24	9M25	YoY
P&L												
Revenue	848	809	833	1,062	1,061	1,094	25%	0%	-3%	2,397	2,956	23%
Gross profit	323	293	298	376	381	387	18%	1%	-2%	914	1,054	15%
Operating profit	161	115	178	155	158	176	-2%	2%	-10%	452	490	9%
Net profit	126	114	156	124	142	130	12%	14%	9%	357	422	18%
BS												
Sh. Equity	3,415	3,469	4,061	4,135	4,226		24%	2%		3,415	4,226	24%
Ratios												
GPM	38.1%	36.2%	35.7%	35.4%	35.9%	35.4%				38.1%	35.7%	
OPM	19.0%	14.3%	21.4%	14.6%	14.8%	16.1%				18.8%	16.6%	
NPM	14.9%	14.1%	18.7%	11.7%	13.4%	11.9%				14.9%	14.3%	
EPS, SAR	1.29	1.17	1.59	1.23	1.40	1.29				3.66	4.22	
RoE (TTM)					13.5%							
TTM P/E (x)					28.4							
Current P/B (x)					3.6							

Source: Financials, Tadawul, Bloomberg, U Capital Research

Current Market Price (SAR)	150.0
52wk High / Low (SAR)	164.0/109.0
12m Average Vol. (mn)	0.1
Mkt. Cap. (USD/SAR mn)	4,063/15,236
Shares Outstanding (mn)	101.6
Free Float (%)	48.0%
3m ADTV (SAR mn)	9.2
6m ADTV (SAR mn)	9.3
P/E'26e (x)	29.5
EV/EBITDA'26e (x)	19.4
Dividend Yield '26e (%)	1.5%
Price Perf. (1m/3m) (%)	3.1/10.3

Research DepartmentEmail: ubhar-research@u-capital.netFor our
last report



Investment Research

Ubhar-Research@u-capital.net

Head of Research

Tahir Abbas

+968 2494 9036 | tahir@u-capital.net

Research Team

Ahlam Al Harthi

+968 2494 9024 | ahlam.harthi@u-capital.net

Sandesh Shetty

+968 2494 9059 | sandesh@u-capital.net

Amira Al Alawi

+968 2494 9012 | amira.alalawi@u-capital.net

Rao Aamir Ali

+968 2494 9066 | Rao@u-capital.net

Head of Brokerage

Talal Al Balushi

+968 2494 9051 | talal@u-capital.net

Visit us at

www.u-capital.net

Disclaimer

Recommendation

BUY	ACCUMULATE	HOLD	REDUCE	SELL
Greater than 20%	Between +10% and +20%	Between +10% and -10%	Between -10% and -20%	Lower than -20%

Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net

PO Box 1137, PC 111, Sultanate of Oman

Tel: +968 2494 9036 | **Fax:** +968 2494 9099 | **Email:** research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.